

Atopic Dermatitis Enrollment Form



Fax Referral To: 1-855-297-1270

Address: 6020 Ave Roberto Sanchez Vilella Carolina, PR 00982

Phone: 1-888-280-1190

NCPDP: 4026325

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name: _____ DOB: _____ Gender: ☐ Male ☐ Female

Address: _____ City, State, ZIP Code: _____

Preferred Contact Methods: ☐ Phone (to primary # provided below) ☐ Text (to cell # provided below) ☐ Email (to email provided below)

Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone: _____ Alternate Phone: _____

Email: _____ Last Four of SSN: _____ Primary Language: _____

Parent/Caregiver/Legal Guardian Name (Last, First): _____ Relationship to patient: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____

NPI #: _____ DEA #: _____ Group or Hospital: _____

Address: _____ City, State, ZIP Code: _____

Phone: _____ Fax: _____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

Is the Patient Insured? ☐ Yes ☐ No Is the Patient enrolled or eligible for Medicare/Medicaid? ☐ Yes ☐ No

Policy Holder's Name: _____ Policy Holder's DOB: _____ Relationship to Patient: _____

Medical Insurance: _____ Telephone: _____ Policy ID: _____ Group #: _____

Prescription Insurance: _____ Prescription Plan Telephone: _____

Policy ID: _____ Group #: _____ RX BIN #: _____ RX PCN #: _____

☐ Check box if patient is enrolled in manufacturer copay assistance If yes, please provide ID# _____

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Ship to: ☐ Patient ☐ Office ☐ Other: _____

Diagnosis (ICD-10):

☐ L20.9 Atopic Dermatitis, Unspecified ☐ Other Code: _____ Description: _____

Patient Clinical Information:

Allergies: _____ Weight: _____ lb/kg Height: _____ in/cm TB Test Result: _____ Date: _____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Adbry	☐ 2 x 150 mg/mL PFS ☐ 4 x 150 mg/mL PFS ☐ 1 x 300 mg/2 mL PEN ☐ 2 x 300 mg/2 mL PEN	Adult Loading Dose: ☐ Inject 600 mg (4 x 150 mg/mL pre-filled syringes) SC on Day 1 ☐ Inject 600 mg (2 x 300 mg/2 mL PEN) SC on Day 1	Quantity: ☐ 4 x 150 mg/mL PFS ☐ 2 x 300 mg/2 mL PEN Refills: <u>0</u>
		Adult Maintenance Dose: ☐ Inject 300 mg SC every other week Adult Maintenance Dose (After Week 16, if patient achieves clear or almost clear skin and weighs < 100 kg): ☐ Inject 300 mg SC every 4 weeks	Quantity: ☐ 28 days ☐ 84 days Refills: _____
		Pediatric Loading Dose (>12 y/o): ☐ Inject 300 mg (2 x 150 mg/mL pre-filled syringes) SC Day 1	Quantity: ☐ 2 x 150 mg/mL PFS Refills: <u>0</u>
		Pediatric Maintenance Dose (>12 y/o): ☐ Inject 150 mg (1 x 150 mg/mL pre-filled syringe) SC every other week	Quantity: ☐ 2 x 150 mg/mL PFS ☐ 28 days ☐ 84 days Refills: _____
☐ Cibinqo	☐ 50 mg ☐ 100 mg ☐ 200 mg	☐ Take 1 tablet by mouth once daily ☐ Other: _____	Quantity: _____ Refills: _____

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Atopic Dermatitis Enrollment Form

Please Complete Patient, Prescriber and Patient Clinical Information

Patient Name: _____ Patient DOB: _____ Patient Phone: _____

Patient Address: _____

Prescriber Name: _____ Prescriber Phone: _____

Patient Clinical Information:

Allergies: _____

Weight: _____ lb/kg Height: _____ In/cm TB Test Result: _____ Date: _____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Dupixent	For use in patients ≥ 6 months and older: ☐ 200 mg/1.14 mL (Carton of two pre-filled syringes with needle shield) ☐ 300 mg/2 mL (Carton of two pre-filled syringes with needle shield) For use in patients ≥ 2 years of age and older: ☐ 200 mg/1.14 mL (Carton of two single dose pre-filled pens) ☐ 300 mg/2 mL (Carton of two single dose pre-filled pens)	Adult Patients: ☐ 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every other week thereafter Pediatric Patients (6 months to 5 years of age): 5 to less than 15 kg: ☐ 200 mg (one pre-filled syringe) every 4 weeks 15 to less than 30 kg: ☐ 300 mg (one pre-filled syringe) every 4 weeks Pediatric Patients (6 years to 17 years of age) 15 to less than 30 kg: ☐ 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every 4 weeks thereafter 30 to less than 60 kg: ☐ 400 mg (two 200 mg injections) subcutaneously on Day 1, then 200 mg subcutaneously every 2 weeks thereafter 60 kg or more: ☐ 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every 2 weeks thereafter	Quantity: _____ (# of injections) Refills: _____
☐ Ebglyss	☐ 250 mg/2 mL PEN ☐ 250 mg/2 mL PFS	Induction Dose (≥ 12 y/o who weigh ≥ 40 kg) ☐ Week 0 and 2: Inject 500 mg (two 250 mg injections) SC every 2 weeks ☐ Week 4-14: Inject 250 mg (one injection) SC every 2 weeks Maintenance Dose (Week 16 or later, when adequate clinical response is achieved): ☐ Inject 250 mg SC every 4 weeks	Quantity: _____ ☐ 28 days ☐ 84 days Refills: _____
☐ Nemluvio	☐ 30 mg/0.49 mL PEN	Induction Dose: ☐ Inject 60 mg (two 30 mg injections) SC followed by 30 mg given every 4 weeks Maintenance Dose: ☐ Inject 30 mg SC every 4 weeks (After 16 weeks of treatment, for patients who achieve clear or almost clear skin): ☐ Inject 30 mg SC every 8 weeks	Quantity: 28 DS Refills: <u>0</u> Quantity: 28 DS Refills: _____ Quantity: 56 DS Refills: _____
☐ Rinvoq	☐ 15 mg ☐ 30 mg	☐ Take 1 tablet by mouth once daily ☐ Other: _____	Quantity: _____ Refills: _____
☐ Other:	☐ Other: _____	☐ Other: _____	Quantity: _____ Refills: _____

☐ Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.